Skip to main content
Premium Trial:

Request an Annual Quote

Lander Lashes Out Against Celera s Sequencing Method, Outlines Plans

CAMBRIDGE, Mass., March 27 – Eric Lander, director of the Whitehead/MIT Genome
Sequencing Center and a key figure in the publicly-funded effort to sequence the human, sharply criticized Celera’s whole genome sequencing method on Tuesday, saying there “is no evidence” the approach worked.

Addressing Harvard’s Genomics 2001 conference in the keynote speech, Lander, who also discussed current public projects, said Celera used the Human Genome Project's sequence data, which contained about 90 percent of the sequence of the genome, for input into its whole genome shotgun assembler.

"If you use a source of data with 90 percent of the genome, put it in, and get 90 percent at the end, one does occasionally wonder where the beef is," Lander said. "At the moment there is no evidence that the whole genome shotgun method worked at all for the human genome."

Nevertheless, Lander said that researchers from the Human Genome Project and Celera were still planning to meet for a workshop to compare and analyze the data. The workshop was first proposed when the two groups published their papers in February.

He also said the public-private Mouse Sequencing Consortium will finish sequencing the mouse using the whole genome shotgun sequencing method, within “the next couple of weeks.” The consortium, which is funded by Affymetrix, GlaxoSmithlkine, the Merck Genome Research Institute, National Institutes of Health, and the Wellcome Trust, has been working to provide three-fold random shotgun coverage of the  "black six" or C57BL6/J mouse for inclusion in the public databases. Celera has completed the sequence and assembly of a mouse genome, but the data is only available to its subscribers.

Meanwhile, as groups look for the next model organism genome to unravel, Lander said he has read a few proposals from groups wanting to sequence the chimpanzee genome. "There's tremendous interest in sequencing the chimp," he said. But Lander indicated that having another higher organism sequenced might not add that much given that scientists still have such a limited understanding of the functions of genes. "We don't even know what genes are important at the regulatory level," Lander said.

While there is an international effort afoot to sequence the chimp, other prominent scientists, including Craig Venter, president of Celera, have also reportedly stated their doubts about the usefulness of sequencing the chimp at this time.

Lander and other scientists from the Human Genome Project are beginning to analyze different areas of the genome that are conserved between mouse and human to gain a clue to function. They also are seeking to discover functional significance by exploring small variations within the human genome – a single SNP in an exon, when linked to phenotypic variation, can provide clues to the function of this exon, he noted.

Luckily, said Lander, the human genome varies little from person to person. Rather than thinking of the human race as a population of 6 billion individuals, Lander said it is more accurate to think of humans as a population of about 10,000 people from the birthplace of humanity, in central Africa, that has changed little in the last 5,000 generations. "We're walking around today with the genome we walked out of Africa with."

Because of this striking similarity, Lander said he thought it would be possible to construct a full map of genetic variations for different subsets of the human population. But meanwhile, he said, scientists have to finish the human genome. Last summer, he said, "the taxi driver would be telling me the whole human genome has been sequenced, and I'd be scratching my head, wondering why am I going back to the lab to work on it?"

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.